CHEK2 and breast cancer: Overall, these data provide some of the first evidence for divergences in the causal impact of ATM, CHK2, and ATR inactivation on the type of breast cancer a patient develops and on disease progression, i.e., metastatic potential and responsiveness to endocrine therapies (Fig. 8I).